Compare Colgate-Palmolive Company (CL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Colgate-Palmolive Company vs State Street SPDR S&P Biotech ETF — how do they compare? Colgate-Palmolive Company trades at $92.22 (market cap $73.59B), while State Street SPDR S&P Biotech ETF trades at $159.1. The key difference: Colgate-Palmolive Company pays a 2.3% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Colgate-Palmolive Company nearer its low. Which is the better fit depends on your goals.
| CL | XBI | |
|---|---|---|
Market Cap | $73.59B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $99.14 | $164.28 |
52-Week Low | $74.98 | $86.92 |
Enterprise Value | $80.07B | — |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Colgate-Palmolive (CL) trades at $93.15, down 0.13% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 EPS of $0.99, beating estimates, with 4.9% sales growth driven by emerging markets. However, North American weakness persists, and valuation ratios like P/E of 36.34 and P/B of 311.81 appear elevated. Cash flow remains positive, and a dividend of $0.53 is scheduled for August 2026.
Outlook is mixed: strong brand presence and dividend sustainability support the stock, but high valuation and domestic challenges pose risks. Analyst consensus price target is $99.10, implying modest upside, with 42% buy ratings. Key risks include competitive pressures and margin compression from inflation.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
